[
  {
    "ts": "2025-12-22T01:09:05+00:00",
    "headline": "Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results",
    "summary": "Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...",
    "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "80294591-caf0-3a07-b84c-e48e6b7368bf",
      "content": {
        "id": "80294591-caf0-3a07-b84c-e48e6b7368bf",
        "contentType": "STORY",
        "title": "Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results",
        "description": "",
        "summary": "Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...",
        "pubDate": "2025-12-22T01:09:05Z",
        "displayTime": "2025-12-22T01:09:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGlsZQabpZKiecAhuIM4vQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/whFiaQBgqA5L2OMhKv37Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALPMF"
            },
            {
              "symbol": "4503"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]